Fig. 3. Identification of essential ASH2L IDRs in DPY30-mediated stimulation.

a Human ASH2L deletion mutants used in (b–d) and transactivation peptides used in (c) and (d). b Serial deletion to map essential ASH2L Linker IDRs for DPY30 function. In vitro HMT assay for the MLL1 core complex containing wild-type or various ASH2L mutants as indicated on top. The assays were performed in the presence or absence of DPY30. c–d Trans-activation experiments using two fragments of ASH2L in the in vitro HMT assay. The MLL1 core complexes containing a mixture of two stoichiometric ASH2L fragments were used with or without DPY30 as indicated on top. #, indicates abolishment of DPY30-dependent activity. Quantification completed using ImageJ¹⁰⁸ with %activity calculated relative to wild-type ASH2L-containing complex.